Phase 1/2/3

MBX Biosciences prepares for the Jefferies conference, with investors eyeing updates on its late-stage hypoparathyroidism drug and promising obesity portfolio.

With a novel two-in-one device and a $41M funding boost, Cagent Vascular is poised to challenge the standard of care for complex calcified arteries.

A $290M war chest fuels a new public biotech aiming to help millions of migraine patients who don't respond to current blockbuster therapies.

A new bispecific antibody, TRIV-573, enters clinical trials, targeting both skin barrier and inflammation to redefine atopic dermatitis therapy.

Contineum Therapeutics reports encouraging early data for its non-opioid drug PIPE-791, offering a potential new weapon in the fight against chronic pain.

A novel immunotherapy that freezes and infuses tumors shows an 87% response rate in advanced prostate cancer, aiming to turn local treatment into a systemic attack.

A $500K grant accelerates a novel therapy that dismantles tumor defenses, offering new hope for patients with hard-to-treat gastroesophageal cancers.

New long-term data for FLT201 gene therapy could signal a paradigm shift from lifelong treatments for patients with Gaucher disease type 1.

A new once-daily pill for hypoparathyroidism begins human testing, promising to replace burdensome injections and transform patient care. Is this the future?

Abbisko's irpagratinib gets EMA Orphan Drug status, fast-tracking a precision therapy for a hard-to-treat liver cancer subgroup with unmet needs.

A new FDA-cleared device uses water vapor to ablate prostate tissue, showing high efficacy in trials while minimizing life-altering side effects.

With a cash runway into 2027, the biotech firm prepares for critical data on its innovative bispecific antibody pipeline for hard-to-treat solid tumors.

A new biotech spins out with a novel drug class aiming to provide healthier, more durable weight loss and combat cancer-related wasting syndrome.

With a $35 million boost from RA Capital, Equillium extends its cash runway to 2029, fueling the clinical development of its promising oral UC therapy, EQ504.

With strong revenue growth and critical FDA decisions on the horizon, MannKind's leadership prepares to outline its vision for investors in Miami.

Neurizon Therapeutics has started dosing its promising ALS drug, NUZ-001, in the groundbreaking HEALEY Platform Trial, a pivotal step for patients.

A new collaboration is betting on tiny natural particles to deliver a gene-editing cure for a devastating neurological disorder, bypassing a key medical hurdle.

With stellar clinical data and a full war chest, Terns is hitting the road to convince investors its leukemia drug, TERN-701, is a true disruptor.

Promising trial data for onvansertib offers new hope for colorectal cancer patients, yet leadership changes and financial hurdles cloud the path forward.

A planned reverse merger for promising vaccine developer SVF Vaccines has collapsed after Nasdaq rejected the deal, leaving its lead investor scrambling.